



Published in final edited form as:

J Inherit Metab Dis. 2023 July ; 46(4): 720–734. doi:10.1002/jimd.12619.

A mouse mutant deficient in both neuronal ceroid lipofuscinosis-associated proteins CLN3 and TPP1

David E. Sleat^{1,2}, Whitney Banach-Petrosky¹, Katherine E. Larrimore¹, Yuliya Nemtsova¹, Jennifer A. Wiseman¹, Allison Najafi³, Dymonn Johnson⁴, Timothy A. Poole⁴, Keigo Takahashi⁴, Jonathan D. Cooper^{3,4,5,6}, Peter Lobel^{1,2}

¹Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ, United States of America

Correspondence: David E. Sleat & Peter Lobel, Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ, United States of America., sleat@cabm.rutgers.edu & lobel@cabm.rutgers.edu.

Details of the contributions of individual authors:

David Sleat: Conceptualization, Methodology, Formal analysis, Investigation, Writing – Original Draft, Supervision. **Whitney Banach-Petrosky:** Investigation, Writing – Review and Editing. **Katherine E. Larrimore:** Investigation, Formal Analysis, Writing – Review and Editing. **Yuliya Nemtsova:** Investigation, Writing – Review and Editing. **Jennifer A. Wiseman:** Investigation, Writing – Review and Editing. **Allison Najafi:** Investigation, Writing – Review and Editing. **Dymonn Johnson:** Investigation, Writing – Review and Editing. **Timothy A. Poole:** Investigation, Writing – Review and Editing. **Keigo Takahashi:** Investigation, Writing – Review and Editing. **Jonathan D. Cooper:** Writing – Review and Editing, Supervision. **Peter Lobel:** Conceptualization, Methodology, Formal analysis, Writing – Review and Editing, Supervision.

A competing interest statement:

Peter Lobel and **David E. Sleat** have received royalty payments as Inventors on Patent 8029781 “Methods of treating a deficiency of functional tripeptidyl peptidase I (CLN2) protein,” which is licensed to BioMarin Pharmaceutical Inc. Other authors have declared that no conflicts of interest exist.

Details of ethics approval or a statement that it was not required for all research studies:

Ethics approval was not required for this research study.

If vertebrate animals have been utilized, documentation of approval from the Institutional Committee for Care and Use of Laboratory Animals (or comparable committee):

Animals were maintained and used following protocols approved by the Rutgers University and Robert Wood Johnson Medical School Institutional Animal Care and Use Committee protocol I09-0274-4.

A list of approximately six keywords; this is of particular importance for recognition of the manuscript after publication by some search engines:

neuronal ceroid lipofuscinosis; mouse; tripeptidyl peptidase 1; CLN3 protein

An availability of data and material statement must be provided by all manuscripts from 1 January 2022. Data availability statements should provide information on where data supporting the results reported in the article can be found including, where applicable, hyperlinks to publicly archived datasets analysed or generated during the study:

Mass spectrometry files (mgf and raw files, GPM search files, and Excel files denoting protein assignments, peptide-spectrum matches and corresponding reporter ion intensities) are archived in the MassIVE (<http://massive.ucsd.edu>) and ProteomeXchange (<http://www.proteomexchange.org/>) repositories in submission MSV000087613. Survival of wild-type C57BL/6 mice was obtained from Jackson Laboratories (<https://phenome.jax.org/projects/Yuan2>).

General Rules:

All Authors confirm:

- absence of previous similar or simultaneous publications,
- their inspection of the manuscript,
- their substantial contribution to the work (all authors should have been involved in (a) conception and design, or analysis and interpretation of data, and (b) drafting the article or revising it critically for important intellectual content), and
- their agreement to submission.

Name of one author who serves as guarantor for the article:

David E Sleat

²Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers Biomedical Health Sciences, Rutgers University, Piscataway, NJ, United States of America

³The Lundquist Institute (formerly Los Angeles Biomedical Research Institute), Harbor-UCLA Medical Center, and David Geffen School of Medicine, University of California, Los Angeles, Torrance, CA United States of America

⁴Departments of Pediatrics, Division of Genetics and Genomic Medicine, Washington University in St Louis, School of Medicine, St Louis, MO, United States of America

⁵Genetics, Division of Genetics and Genomic Medicine, Washington University in St Louis, School of Medicine, St Louis, MO, United States of America

⁶Neurology, Division of Genetics and Genomic Medicine, Washington University in St Louis, School of Medicine, St Louis, MO, United States of America

Abstract

Late-infantile neuronal ceroid lipofuscinosis (LINCL) and juvenile neuronal ceroid lipofuscinosis (JNCL) are inherited neurodegenerative diseases caused by mutations in the genes encoding lysosomal proteins tripeptidyl peptidase 1 (TPP1) and CLN3 protein, respectively. TPP1 is well-understood and, aided by animal models that accurately recapitulate the human disease, enzyme replacement therapy has been approved and other promising therapies are emerging. In contrast, there are no effective treatments for JNCL, partly because the function of the CLN3 protein remains unknown but also because animal models have attenuated disease and lack robust survival phenotypes. Mouse models for LINCL and JNCL, with mutations in *Tpp1* and *Cln3* respectively, have been thoroughly characterized but the phenotype of a double *Cln3/Tpp1* mutant remains unknown. We created this double mutant and find that its phenotype is essentially indistinguishable from the single *Tpp1*^{-/-} mutant in terms of survival and brain pathology. Analysis of brain proteomic changes in the single *Tpp1*^{-/-} and double *Cln3*^{-/-}; *Tpp1*^{-/-} mutants indicates largely overlapping sets of altered proteins and reinforces earlier studies that highlight GPNMB, LYZ2 and SERPINA3 as promising biomarker candidates in LINCL while several lysosomal proteins including SMPD1 and NPC1 appear to be altered in the *Cln3*^{-/-} animals. An unexpected finding was that *Tpp1* heterozygosity significantly decreased lifespan of the *Cln3*^{-/-} mouse. The truncated survival of this mouse model makes it potentially useful in developing therapies for JNCL using survival as an endpoint. In addition, this model may also provide insights into CLN3 protein function and its potential functional interactions with TPP1.

1. Introduction

The neuronal ceroid lipofuscinoses (NCLs) are a group of more than a dozen genetically-distinct but similar lysosomal storage diseases (Mole et al 2011). Characterized by an accumulation of autofluorescent storage material within the lysosome, NCLs are neurodegenerative and progressive diseases that are manifested by seizures, loss of vision, and eventual loss of mental capacity. Onset is typically in childhood and these diseases result in premature death. Two of the most frequently encountered NCL diseases are the classical late-infantile and juvenile forms (LINCL and JNCL, respectively). LINCL results

from mutations in the gene encoding tripeptidyl peptidase 1 (TPP1, formerly designated CLN2) (Sleat et al 1997; Sleat et al 1999), a soluble lysosomal serine protease (Rawlings and Barrett 1999; Vines and Warburton 1999; Sohar et al 2000). Disease in LINCL typically presents at around 4 years of age and lifespan is ~8 to 15 years (Mole et al 2011). JNCL is caused by mutations in a gene encoding a lysosomal transmembrane protein, CLN3 (Consortium 1995). JNCL has a later onset and is more slowly progressing than LINCL, with first signs of disease (typically problems with vision) at around 8 years and patients frequently surviving into second or third decade of life (Mole et al 2011). Despite differences in disease timeline and genetic etiology, LINCL and JNCL have a number of similarities including lysosomal storage of subunit c of mitochondrial ATP synthase (SCMAS) (Palmer et al 1989).

There is considerable focus on the development of effective therapies for NCL diseases and LINCL is leading the way. Enzyme replacement therapy has been clinically approved for LINCL (Schulz et al 2018; de Los Reyes et al 2020) and there is interest in gene therapy, with promising results obtained in animal models (Passini et al 2006; Cabrera-Salazar et al 2007; Sondhi et al 2007; Worgall et al 2008; Katz et al 2015), and clinical studies have been conducted (Crystal et al 2004; Hackett et al 2005). Both enzyme replacement therapy (ERT) and gene-therapy rely upon the fact that TPP1 is a soluble lysosomal protein (Sleat et al 1997). In ERT, exogenously-administered recombinant protein can be taken up by numerous cells by endocytosis and delivered to the lysosome, while in gene therapy, only a proportion of cells are transduced but these can overproduce and secrete enzyme that is taken up by untransduced cells. In addition, there are LINCL animal models (Sleat et al 2004; Awano et al 2006) with well-defined phenotypes that accurately recapitulate the human disease and these have been integral in testing treatment strategies.

There is currently no approved therapy for JNCL and this reflects several major obstacles. First, CLN3 is a transmembrane protein (Consortium 1995), which excludes replacement treatment using exogenously administered recombinant protein. There is interest in gene therapy for JNCL (Sondhi et al 2014) but because CLN3 is an integral membrane protein, non-transduced cells will not express the missing protein. Thus, if the underlying metabolic defect is cell autonomous, cross-protection between transduced and untransduced cells may not be possible, and a very high proportion of cells will require transduction for effective therapy. Second, there is a fundamental lack of understanding of the cellular function of the CLN3 protein. It has been implicated in numerous cellular activities including lysosomal pH homeostasis, endocytosis, autophagy, apoptosis, lysosomal enzyme transport, and others (Carcel-Trullols et al 2015). While precise function of CLN3 is yet to be definitively established, a recent study has established that glycerophosphodiesterases accumulate within the lysosome in the absence of CLN3 (Laqtom et al 2022), raising the possibility the CLN3 is a lysosomal transporter for these lipids. Regardless, mechanism-based approaches to treatment for JNCL are currently not an option. Third, animal models for JNCL do not present a robust phenotype, especially with respect to survival. There are several mouse models for JNCL (Katz et al 1999; Mitchison et al 1999; Cotman et al 2002; Langin et al 2020) and their phenotypes are very similar but in all, disease is highly attenuated compared to mouse models of other NCL diseases.

In this study, we have created mice that are defective in both CLN3 protein and TPP1 with the rationale that the phenotype of a double mutant may provide insights into CLN3 protein function and possible functional interactions with TPP1. In terms of survival, pathology and proteomic changes within the brain, the phenotype of the double mutant is essentially indistinguishable from mice that lack TPP1 alone. However, we find that the lifespan of the *Cln3*^{-/-} mouse model is shortened in a *Tpp1* heterozygous background. While the physiological implications of this are unclear, this does potentially provide a mouse model with a clear JNCL survival phenotype that may be of value in therapeutic testing.

2 Methods

2.1 Animals

Mice were maintained and used following protocols approved by the Rutgers University and Robert Wood Johnson Medical School Institutional Animal Care and Use Committee (“Preclinical evaluation of therapy in an animal model for LINCL,” protocol I09-0274-4). *Tpp1*^{-/-} mice (Sleat et al 2004) were either in an *Nnt*^{-/-} (Mekada et al 2009) C57BL/6J or *Nnt*^{+/+} C57BL/6 strain background. *Cln3*^{-/-} mice (Greene et al 1999) were in a C57BL/6J genetic background. Animals arising from crosses between C57BL/6 *Tpp1*^{-/-} mice and C57BL/6J *Cln3*^{-/-} mice are in a mixed C57BL6 substrain background designated here as C57BL/6×6J and they are a mixture of *Nnt*^{+/+}, *Nnt*^{+/-} and *Nnt*^{-/-} genotypes. Genotyping of *Tpp1*^{-/-} and *Cln3*^{-/-} mice was conducted as described (Greene et al 1999; Sleat et al 2004). Experimental cohorts contained ~equal numbers of males and female animals and were analyzed at ~120 days of age. For biochemical analyses, animals were deeply anesthetized with sodium pentobarbital/phenytoin (a 1:4 dilution of Euthasol; Delmarva Laboratories, Midlothian, VA) and euthanized by transcardial perfusion with 0.9% saline. Brains were dissected and frozen on dry ice. For histopathology, mice were anesthetized, perfused with saline then perfusion-fixed with 4% paraformaldehyde in PBS. Brains were excised, fixed for 48 hrs in 4% paraformaldehyde in PBS, and then transferred to 30% sucrose/PBS at 4°C until they sunk.

2.2 Quantitative mass spectrometry

Sample preparation and quantitative mass spectrometry on whole brain extracts was conducted as described previously (Sleat et al 2019) and parameters for mass spectrometry, peak list generation and database searching are summarized in Table S1. In brief, detergent solubilized extracts were prepared, proteins were digested in-solution sequentially with trypsin (specificity, carboxyl side of K and R) and endoprotease LysC (specificity, carboxyl side of K) and the resulting peptides labeled with TMT11-plex isobaric reagents (ThermoFisher Scientific). Labeled samples were pooled and analyzed by synchronous precursor selection MS3 on a Lumos Tribrid instrument (ThermoFisher Scientific).

2.3 Database searching

Peak lists were generated using Proteome Discoverer 2.2 (ThermoFisher Scientific) and data were searched using a local implementation of the Global Proteome Machine (GPM) (Craig et al 2004; Beavis 2006) using search parameters shown in Table S1. Protein assignments are shown in Table S2. Mass spectrometry files (mgf and raw

files, GPM search files, and Excel files denoting protein assignments, peptide-spectrum matches and corresponding reporter ion intensities) are archived in the MassIVE (<http://massive.ucsd.edu>) and ProteomeXchange (<http://www.proteomexchange.org/>) repositories in submission MSV000087613.

2.4 Normalization and statistical analyses of mass spectrometry data

TMT-16 reporter ion intensities were normalized and analyzed as described previously (Sleat et al 2017). In brief, reporter ion intensity data were extracted from peak list files using custom in-house scripts (<https://github.com/cgermain/IDEAA>), then spectra were normalized to total reporter ion intensity per channel to correct for differences in labeling efficiency and/or amounts of protein labeled. Spectral assignments with reporter ion intensities are shown in Table S2. Peptides were first filtered for fully tryptic cleavage, no missed cleavage sites, and complete iTRAQ labeling of lysines and amino termini. Peptides were then filtered to remove those containing posttranslational modifications that may increase variability in the data (i.e., asparagine or glutamine deamidation, methionine dioxidation, tryptophan mono- and dioxidation, and isobaric labeling of tyrosine at positions other than the amino terminus). For selected comparisons, ratios of expression and q-values corrected for multiple comparisons using the Benjamini-Hochberg procedure (Benjamini and Hochberg 1995) were generated using a nested procedure that accounts for variability at both peptide and protein level (Sleat et al 2017) (Table S3).

2.5 Immunostaining

For immunohistochemistry, a one in six series of coronal brain sections from each mouse were stained using a modified immunofluorescence protocol (Nelvagal et al 2021) for the astrocyte marker glial fibrillary associated protein (GFAP, rabbit anti-GFAP, 1:1000, DAKO), and the microglial marker CD68 (rat anti-mouse CD68, 1:400, Bio-Rad). Briefly, 40µm coronal sections were mounted on Superfrost Plus slides (Fisher Scientific) and air-dried for 30 mins, slides were then blocked in a 15% serum solution in 2% TBS-T (1x Tris Buffered Saline, pH 7.6 with 2% Triton-X100, Fisher Scientific) for 1 hour. Slides were then incubated in primary antibody in 10% serum solution in 2% TBS-T for 2 hours, washed three times in 1xTBS and incubated with fluorescent Alexa-Fluor labelled IgG secondary antibodies (Alexa-Fluor goat anti-rabbit 488, goat anti-rat 546, Invitrogen) in 10% serum solution in 2% TBS-T for 2 hours. Slides were washed three times in 1xTBS and incubated in a 1x solution of TrueBlack lipofuscin autofluorescence quencher (Biotium, Fremont, CA) in 70% ethanol for 2 mins before rinsing with 1xTBS. Slides were cover-slipped in Fluoromount-G mounting medium with DAPI (Southern Biotech, Birmingham, AL).

2.6 Thresholding image analysis

To analyze the degree of glial activation in the gray matter (GFAP positive astrocytes + CD68 positive microglia) a semiautomated thresholding image analysis method was used with *Image-Pro Premier software* (Media Cybernetics). Briefly, stained sections were scanned using a Zeiss AxioScan Z1 slide scanner at the Washington University Center for Cellular Imaging (WUCCI), at 10x magnification of each one in six series of sections per animal followed by demarcation of all regions of interest. Images were subsequently analyzed using *Image-Pro Premier* (Media Cybernetics) using an appropriate threshold

that selected the foreground immunoreactivity above background. This threshold was then applied as a constant to all subsequent images analyzed per batch of animals and reagent used to determine the specific area of immunoreactivity for each antigen. Measurements for histological processing were performed blind to genotype and statistical analyses were performed using GraphPad Prism version 8.0.0 for MacOS. Data were analyzed using two-way ANOVA with a post-hoc Bonferroni correction, with a p-value of 0.05 considered significant.

2.7 Survival statistics

Survival curves were compared using log-rank tests in GraphPad Prism 9.1 (GraphPad Software, San Diego, California USA, www.graphpad.com).

2.8 TPP1 enzyme assay

TPP1 was measured using an endpoint assay with Ala-Ala-Phe-AMC substrate as described previously (Sohar et al 2000). For TPP1 assay in the presence of glycerophosphodiesterases, TPP1 activity was again measured by endpoint assay with 200 μ M Ala-Ala-Phe-AMC and 1 or 10 mM L- α -Glycerophosphorylcholine (Sigma) or 100 μ M Glycerophosphoinositol (Echelon), each dissolved in water.

3 RESULTS

3.1 Breeding strategy

Our original plan for generating all required genotypes as littermates was to conduct dihybrid crosses using animals that were heterozygous for both *Tpp1* and *Cln3* mutations. Analysis of transmission ratios indicated that offspring were not generated in the predicted ratios (data not shown) with lower than predicted numbers of both *Tpp1*^{-/-};*Cln3*^{-/-} and *Tpp1*^{+/+};*Cln3*^{+/+} animals. This reflects gene linkage with both *Tpp1* and *Cln3* located on chromosome 7 in the mouse (*Tpp1* Location: Chr 7 E3; 7 55.97 cM, *Cln3* Location: Chr 7 F3; 7 69.16 cM). Subsequently, double knockout animals were generated by *Tpp1*^{-/-};*Cln3*^{-/-} \times *Tpp1*^{-/-};*Cln3*^{-/-} or *Tpp1*^{-/-};*Cln3*^{-/+} \times *Tpp1*^{+/+};*Cln3*^{-/-} matings.

3.2 Survival

Survival curves and statistical comparisons are shown in Fig. 1, and Table 1. Given the substantial differences in survival, animals on a *Tpp1*^{-/-} background are shown in Fig. 1A and animals on a *Tpp1*^{+/-} or *Tpp1*^{+/+} background are shown in Figs. 1B and 1C.

Tpp1^{-/-};*Cln3*^{-/-}, *Tpp1*^{-/-};*Cln3*^{+/-} and *Tpp1*^{-/-};*Cln3*^{+/+} animals in the mixed C57BL/6 \times 6J background had median survivals between 120–124 days (Table 1). Survival of *Tpp1*^{-/-};*Cln3*^{-/-} (median 124 days) was slightly but significantly (p=0.0114) shorter than *Tpp1*^{-/-};*Cln3*^{+/+} littermates (median 120 days) and the survival curve of *Tpp1*^{-/-};*Cln3*^{-/-} mice was somewhat rectangularized compared to the *Tpp1*^{-/-};*Cln3*^{+/+} mice (Fig. 1A). This may be an effect of the *Cln3* mutation on the *Tpp1*^{-/-} phenotype but most likely reflects a subtle difference in the genetic background of the animals. The *Tpp1* mutant allele used for these studies was backcrossed against C57BL/6 (Sleat et al 2004) as was the *Cln3* allele (Hersrud et al 2016). However, the substrain background of the two mutants differ

in that the *Tpp1*^{-/-} mice were *Nnt*^{+/+} while the *Cln3*^{-/-} mice were *Nnt*^{-/-} (Sleat et al 2019). Mutations in *Nnt* vary in different C57BL/6 substrains (Mekada et al 2009) and the *Nnt*^{-/-} genotype arose at Jackson Laboratories and is designated as C57BL/6J. Subtle differences in survival likely reflect differences in substrain given that isogenic *Tpp1*^{-/-} mice in an *Nnt*^{-/-} C57BL/6J background have a significantly ($p < 0.0001$) shorter lifespan (median 112 days) as the same mutant in the isogenic *Nnt*^{+/+} C57BL/6 background (median 137 days). Regardless, the primary conclusion is that there was no marked difference in survival phenotype of the *Tpp1*^{-/-} *Cln3*^{-/-} double mutant and *Tpp1*^{-/-} *Cln3*^{+/+} single mutant animals.

Survival of mutant animals in *Tpp1*^{+/-} or *Tpp1*^{+/+} backgrounds are shown in Figs. 1B and C. Note that we collected limited survival data for wild-type animals and therefore include data from C57BL/6J animals from another study (“Yuan dataset”) (Yuan et al 2012). Survival of *Tpp1* heterozygotes did not differ significantly ($p = 0.1635$) from the Yuan dataset of wild-type animals (median survival 901 days) (Fig. 1B). We did not collect survival data for *Tpp1*^{+/+}; *Cln3*^{+/-} animals but given that heterozygosity for *Tpp1* did not affect survival, we predict no significant differences in survival of *Cln3* heterozygotes when compared to wild-type. Survival of *Tpp1*^{+/-}; *Cln3*^{+/-} double heterozygote mice (median 748 days) was similar to the single *Cln3*^{-/-} mice ($p = 0.5719$) and was also significantly shorter than wild-type animals ($p = 0.0014$). *Tpp1* heterozygosity resulted in decreased survival of *CLN3*^{-/-} animals (median 584 days) which was significantly ($p < 0.0001$) shorter than that of the *Tpp1*^{+/+}; *Cln3*^{-/-} animals. Overall, these data indicate that heterozygosity for *Tpp1* resulted in decreased survival of both *Cln3*^{+/-} and *Cln3*^{-/-} animals.

Survival of our *Tpp1*^{+/+}; *Cln3*^{-/-} mice (median 719 days) was not significantly different ($p = 0.2339$) from historical data from a different but similar JNCL knockout mouse model (742 days) (Katz et al 2008) (Fig. 1C). However, survival of both *Cln3* mutants was significantly reduced compared to wild-type mice ($p < 0.0001$).

3.3 Pathology

In order to compare brain pathology in the double mutant *Tpp1*^{-/-} *Cln3*^{-/-} and single mutant *Tpp1*^{-/-} animals, animals were euthanized at their median lifespan of ~120 days. Sections were analyzed by immunofluorescence for the simultaneous detection of markers of glial activation, (CD68 in microglia and GFAP in astrocytes) in two brain regions where pronounced glial activation is consistently observed in multiple NCL mouse models: the barrel field of the somatosensory cortex (S1BF) and the region encompassing the medial and lateral ventral posterior nuclei of the thalamus (VPM/VPL). As expected, immunostaining for either GFAP or CD68 was present at very low levels in animals with a *Tpp1*^{+/-} or *Tpp1*^{+/+} genotype irrespective of *Cln3* genotype. In these animals, only very faintly stained GFAP-positive astrocytes or CD68 positive microglia (Fig. 2) were present. Consistent with previous observations (Chang et al 2008), marked activation of both astrocytes and microglia was detected in the S1BF and VPM/VPL of *Tpp1*^{-/-} *Cln3*^{+/+} animals, with pronounced upregulation of these markers and corresponding changes in cellular morphology. Similar levels of pronounced glial activation were detected in the S1BF and VPM/VPL of double mutant *Tpp1*^{-/-} *Cln3*^{-/-} animals, with similar degrees of cellular hypertrophy of both astrocytes and microglia apparent to those seen in *Tpp1*^{-/-} *Cln3*^{+/+}

animals. Thresholding image analysis confirmed these qualitative observations with significant elevation of both GFAP and CD68 immunoreactivity in both brain regions of *Tpp1^{-/-}Cln3^{+/+}* and *Tpp1^{-/-}Cln3^{-/-}* animals compared to other genotypes (Fig. 3). Although the individual levels of GFAP and CD68 immunoreactivity differed to some extent between *Tpp1^{-/-}Cln3^{+/+}* and *Tpp1^{-/-}Cln3^{-/-}* animals, there were no significant differences for either antigen in either brain region between animals of these genotypes. This broad similarity between *Tpp1^{-/-}Cln3^{+/+}* and *Tpp1^{-/-}Cln3^{-/-}* animals in terms of the extent of glial activation is consistent with the similarities observed in the survival phenotypes of these mutants. While we did not measure autofluorescence, lysosomal storage and neuronal loss, we would predict these to be similar or identical in the *Tpp1^{-/-}Cln3^{+/+}* and *Tpp1^{-/-}Cln3^{-/-}* animals given the similarities in glial activation pathology and survival phenotypes. Overall, *Cln3* genotype had no observable effect on pathology of *Tpp1^{-/-}* animals at the age tested (~100 days). This provides further evidence that *Cln3* defects do not exacerbate the LINCL phenotype in these animals.

3.4 Proteomic analysis

We conducted a proteomic analysis on brain samples from the *Tpp1* and *Cln3* mutant mice with the goal of identifying changes that might correlate with disease survival and may shed light on the respective cellular functions of these proteins. In addition, given that earlier proteomic studies failed to identify any informative brain expression changes in *Cln3^{-/-}* mice (Sleat et al 2019), we hypothesized that changes related to *Cln3* mutation could be exacerbated and thus possibly easier to detect in a *Tpp1* mutant background. Proteins in brain extracts from animals at ~105 days were identified and quantified using isobaric labeling mass spectrometry. In Fig. 4, we compared various genotypes of interest using volcano plots, a scatter plot that allows comparison of effect size with probability of significant difference. Q values (i.e., p-values adjusted for multiple comparisons found using the Benjamini-Hochberg false discovery rate method) were calculated by comparing reporter ion intensities for all individual spectra assigned to a given protein from all biological replicates for each genotype.

A number of significant changes in protein expression were detected when *Tpp1^{-/-}* animals were compared with wild-type including elevation of GPNMB, LYZ2, SERPINA3N and various lysosomal proteins including several cathepsins (Table S4). When double mutant *Tpp1^{-/-};Cln3^{-/-}* animals were compared to wild-type, we identified very similar changes in protein expression for the most part as illustrated by the high degree of correlation between fold changes in expression compared to wild-type in *Tpp1^{-/-};Cln3^{+/+}* and *Tpp1^{-/-};Cln3^{-/-}* animals (Fig. 5A). Relatively few changes were detected in the *Cln3^{-/-}* mutant animals in *Tpp1^{+/+}* or *Tpp1^{+/+}* backgrounds but NPC1 and CTSF were consistently elevated while NEU4 and SMPD1 were decreased (Fig. 5B).

3.5 TPP1 activity in mutant mice

Previous studies have reported elevated TPP1 activities in the brains of *Cln3* knockout mice (Mitchison et al 1999). Consistent with these earlier studies, we find that TPP1 activity in the *Cln3* mutant is ~2-fold higher than that measured in wild-type animals, while no activity was detectable in *Tpp1^{-/-}* animals irrespective of *Cln3* genotype (Fig. 6). While previous

analyses (Sleat et al 2004) indicated that TPP1 activity in *Tpp1^{+/-}* animals is, as expected, ~50% of wild-type, TPP1 activity in *Tpp1^{+/-}Cln3^{-/-}* animals is ~100% of wild-type. This again indicates that loss of CLN3 results in an ~2-fold increase in TPP1 activity.

4 DISCUSSION

The overall goal of this study was to determine the phenotype of a double *Tpp1* and *Cln3* mutant mouse model, which may provide useful information regarding the cellular role of CLN3 and potential functional interactions between TPP1 and CLN3. We find that the phenotype of these double knockout mice was similar or identical to the single *Tpp1* mutant: median survival of both models is within five days and they display indistinguishable NCL pathology in the form of astrocytosis and microglial activation.

Glial activation is a consistent pathological feature in NCL diseases, including both LINCL and JNCL (Bosch and Kielian 2015; Cooper et al 2015). Typically, localized glial activation precedes the onset of neuron loss and serves to predict where neurodegeneration subsequently occurs. Indeed, there have been suggestions that glial dysfunction may contribute to neuron loss in multiple NCLs (Cooper et al 2015). Quantitative analysis of *Tpp1^{-/-}Cln3^{+/+}* and *Tpp1^{-/-}Cln3^{-/-}* mice revealed very similar extents of astrocytosis and microglial activation between mice of these genotypes. In future studies, it will be important to determine whether this similarity extends to the degree of neuron loss in these mice. Such investigations lie beyond the scope of the current study but would further raise the translational significance of the newly developed mouse model.

Lifespan of the JNCL mouse model (median 719 days) was somewhat shortened compared to wild-type (median 901 days) and this is consistent with previous analysis of a different *Cln3* knockout mouse model (*Cln3^{-/-}*, median 742 days, wild-type median 868 days, (Katz et al 2008)). Unexpectedly, we found that heterozygosity for *Tpp1* was associated with shortened survival of *Cln3^{-/-}* mice, further decreasing lifespan to a median of 584 days. In addition, survival of a double heterozygote *Tpp1^{+/-};Cln3^{+/-}* was also significantly reduced compared to wild-type.

One possible explanation for this observation is that heterozygosity for *Tpp1* exacerbates the *Cln3* phenotype due to substrain effects given that the *Cln3* knockout mouse is in an *Nnt^{-/-}* C57BL/6J background whereas the *Tpp1* knockout is *Nnt^{+/+}* C57BL/6. As a result, the *Tpp1^{+/-}Cln3^{-/-}* mutant was predicted to be in a mixed *Nnt^{+/+}*, *Nnt^{+/-}* and *Nnt^{-/-}* C57BL/6xJ background and this was confirmed by genotyping *Nnt* in 15 *Tpp1^{+/-}Cln3^{-/-}* mutants: we found the majority (9/15) to be *Nnt^{-/-}*, 5/15 to be *Nnt^{+/-}* and 1/15 to be *Nnt^{+/+}* (data not shown). Thus, most of the *Tpp1^{+/-}Cln3^{-/-}* animals were in an *Nnt^{-/-}* strain background like the *Cln3^{-/-}* mutant. It is also worth noting that an isogenic *Nnt^{-/-}* C57BL/6J background shortens the lifespan of *Tpp1^{-/-}* animals compared to the same mutation in an *Nnt^{+/+}* C57BL/6 background (Fig. 1). Thus, if substrain effects were to play a role in survival, we would predict that the introduction of a wild type *Nnt* allele into the *Tpp1^{+/-}Cln3^{-/-}* animals would actually *increase rather than shorten* survival of the *Cln3^{-/-}* mouse. Taken together, these observations indicate that substrain effects do not play a role in the shortened survival of the *Tpp1^{+/-}Cln3^{-/-}* mouse.

Another possibility is that the loss of the CLN3 protein could have adverse downstream effects on TPP1 function or access to its substrates, potentially causing or contributing to JNCL disease. If this is the case, then heterozygosity for *Tpp1* would be predicted to exacerbate disease. The fact that both LINCL and JNCL accumulate SCMAS, a likely primary substrate for TPP1 (Ezaki et al 2000), and the fact that TPP1 activity is elevated in JNCL (Fig. 6) (Junaid and Pullarkat 1999; Mitchison et al 1999), a possible compensatory response, is consistent with this model. It is also possible that the compensatory increases in TPP1 activity detected in the absence of CLN3 might actually provide a neuroprotective function thus heterozygosity for *Tpp1* would diminish such a protective role, resulting in a shorter lifespan for the *Cln3*^{-/-} mouse. Finally, a recent study (Laqtom et al 2022) indicated that loss of CLN3 results in a lysosomal accumulation of glycerophosphodiesteres, and it is possible that increased levels of these lipids directly inhibit TPP1 function. To test this possibility, we conducted assays of increasing amounts of TPP1 in the presence of 100μM glycerophosphoinositol or 1mM and 10mM glycerophosphocholine, two glycerophosphodiesteres shown to accumulate in the absence of CLN3. Presence of these lipids had no detectable effect on TPP1 activity *in vitro* (Fig. 7) thus we conclude that they do not directly act as inhibitors at the concentrations tested. However, we cannot exclude the possibility that locally higher concentrations of these accumulated lipids within in the lysosome, or complexes between these lipids and other lysosomal material, could have an inhibitory effect on TPP1 under physiological conditions.

Regardless of the underlying basis for its shortened lifespan, decreased survival of the *Tpp1*^{+/-}*Cln3*^{-/-} mutant may be useful for testing of therapeutic strategies for JNCL. In developing any therapeutic strategy, survival provides a clear and objective endpoint: for example, in evaluating several different strategies for LINCL, survival studies in mouse models have highlighted promising approaches (e.g., gene therapy, intrathecal cerebrospinal fluid (CSF)-mediated ERT, bloodstream mediated ERT) (Xu et al 2011; Meng et al 2012; Meng et al 2014; Meng et al 2017; Wiseman et al 2017) while survival studies in the dog model (Katz et al 2015) helped pave the way for the approval of enzyme replacement therapy. LINCL animal models have a markedly shortened lifespan thus proof of principle for treatments in terms of survival is readily achievable. In contrast, survival of *Cln3* mutant mice approaches that of wild-type, complicating survival as an endpoint. As a result, behavioral models have been extensively employed to analyze disease progression and the effects of potential treatment in *Cln3* mutant mice. While numerous studies have characterized locomotor deficits in *Cln3* mouse mutants (Wendt et al 2005; Eliason et al 2007; Katz et al 2008; Weimer et al 2009; Staropoli et al 2012; Kovacs and Pearce 2015), behavioral phenotypes are subtle and are dependent on mouse strain and gender (Kovacs and Pearce 2015).

Evaluation of potential therapeutics for JNCL in *Cln3*^{-/-};*Tpp1*^{+/-} mouse mutants would provide a relatively robust survival phenotype to measure efficacy. In addition, it is likely that behavioral phenotypes would be exacerbated at a younger age. Effective therapy that addresses the loss of CLN3 (e.g., widespread gene therapy throughout the brain) would be predicted to increase survival of this mouse mutant to resemble that of the *Tpp1* heterozygote, which is indistinguishable from wild-type. A similar approach has been conducted using mutant *Cln3* mice that express human amyloid precursor protein (APP)

with familial Alzheimer disease mutations (Centa et al 2020). However, the mutant APP confers a severe survival phenotype even without CLN3 defects, thus positive treatment for CLN3 defects would essentially ameliorate a severe phenotype, not restore wild-type survival.

One goal of this project was to determine whether the double *Tpp1* and *Cln3* knockout could highlight proteomic changes in brain that could potentially provide a platform for clinically useful biomarkers in either or both LINCL and JNCL. Neurofilament light chain (NEFL in mice) has been proposed as a treatment-responsive biomarker based on studies of plasma from CLN2 patients and a dog model (Ru et al 2019) and previously, we found levels of this and other neurofilaments proteins (NEFH and NEFM) to be elevated in mouse CSF (Sleat et al 2019). However, we found brain levels of NEFL, NEFH and NEFM to be unchanged or reduced in the CLN2 and CLN3 mouse models. This is consistent with the finding that brain NEFL is unchanged in mouse models of other neurodegenerative disease exhibiting elevated NEFL plasma and CSF levels (Bacioglu et al 2016). However, this study does reinforce several proteomic changes in LINCL mouse brain that were identified previously including elevated GPNMB, LYZ2 and SERPINA3 (Sleat et al 2019). Further studies on *Tpp1*^{-/-} mouse models will indicate if any of these proteins are also significantly altered in more accessible biological samples including blood and cerebrospinal fluid. We also found that several lysosomal proteins (CTSF, SMPD1 and NPC1) were significantly altered in the *Cln3*^{-/-} animals and while changes in expression were modest, they may be more evident in older mice (animals were analyzed at ~120 days in this study). These changes may be compensatory responses to the loss of CLN3 and could potentially provide useful information regarding its biological function. In addition, soluble lysosomal proteins SMPD1 and CTSF may also warrant further investigation as potential biomarkers in JNCL.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

We thank Dr. Martin Katz (Mason Eye Institute of the University of Missouri School of Medicine) for generously providing survival data for the JNCL mouse model originating from his laboratory.

Details of funding:

This project was supported by a grant from the Batten Disease Support and Research Association, Beyond Batten Disease Foundation and Hope 4 Bridget (D.E.S.) and NIH grants R21NS088786 (D.E.S.), R01NS37918 (P.L.), and institutional support from the Department of Pediatrics, Washington University Medical School, St. Louis (JDC). The authors confirm independence from the sponsors; the content of the article has not been influenced by the sponsors.

REFERENCES

- Awano T, Katz ML, O'Brien DP, et al. (2006) A frame shift mutation in canine TPP1 (the ortholog of human CLN2) in a juvenile Dachshund with neuronal ceroid lipofuscinosis. *Mol Genet Metab* 89: 254–260. [PubMed: 16621647]
- Bacioglu M, Maia LF, Preische O, et al. (2016) Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. *Neuron* 91: 494–496. [PubMed: 27477021]

- Beavis RC (2006) Using the global proteome machine for protein identification. *Methods Mol Biol* 328: 217–228. [PubMed: 16785652]
- Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society: Series B (Statistical Methodology)* 57: 289–300.
- Bosch ME, Kielian T (2015) Neuroinflammatory paradigms in lysosomal storage diseases. *Front Neurosci* 9: 417. [PubMed: 26578874]
- Cabrera-Salazar MA, Roskelley EM, Bu J, et al. (2007) Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease. *Mol Ther* 15: 1782–1788. [PubMed: 17637720]
- Carcel-Trullols J, Kovacs AD, Pearce DA (2015) Cell biology of the NCL proteins: What they do and don't do. *Biochim Biophys Acta* 1852: 2242–2255. [PubMed: 25962910]
- Centa JL, Jodelka FM, Hinrich AJ, et al. (2020) Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten disease. *Nat Med* 26: 1444–1451. [PubMed: 32719489]
- Chang M, Cooper JD, Sleat DE, et al. (2008) Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. *Mol Ther* 16: 649–656. [PubMed: 18362923]
- Consortium IBD (1995) Isolation of a novel gene underlying Batten disease, CLN3. The International Batten Disease Consortium. *Cell* 82: 949–957. [PubMed: 7553855]
- Cooper JD, Tarczylyk MA, Nelvagal HR (2015) Towards a new understanding of NCL pathogenesis. *Biochim Biophys Acta* 1852: 2256–2261. [PubMed: 26026924]
- Cotman SL, Vrbanac V, Lebel LA, et al. (2002) Cln3(Deltaex7/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth. *Hum Mol Genet* 11: 2709–2721. [PubMed: 12374761]
- Craig R, Cortens JP, Beavis RC (2004) Open source system for analyzing, validating, and storing protein identification data. *J Proteome Res* 3: 1234–1242. [PubMed: 15595733]
- Crystal RG, Sondhi D, Hackett NR, et al. (2004) Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. *Hum Gene Ther* 15: 1131–1154. [PubMed: 15610613]
- de Los Reyes E, Lehwald L, Augustine EF, et al. (2020) Intracerebroventricular Cerliponase Alfa for Neuronal Ceroid Lipofuscinosis Type 2 Disease: Clinical Practice Considerations From US Clinics. *Pediatr Neurol* 110: 64–70. [PubMed: 32684372]
- Eliason SL, Stein CS, Mao Q, et al. (2007) A knock-in reporter model of Batten disease. *J Neurosci* 27: 9826–9834. [PubMed: 17855597]
- Ezaki J, Takeda-Ezaki M, Kominami E (2000) Tripeptidyl peptidase I, the late infantile neuronal ceroid lipofuscinosis gene product, initiates the lysosomal degradation of subunit c of ATP synthase. *J Biochem* 128: 509–516. [PubMed: 10965052]
- Greene ND, Bernard DL, Taschner PE, et al. (1999) A murine model for juvenile NCL: gene targeting of mouse Cln3. *Mol Genet Metab* 66: 309–313. [PubMed: 10191119]
- Hackett NR, Redmond DE, Sondhi D, et al. (2005) Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates. *Hum Gene Ther* 16: 1484–1503. [PubMed: 16390279]
- Hersrud SL, Kovacs AD, Pearce DA (2016) Antigen presenting cell abnormalities in the Cln3(−/−) mouse model of juvenile neuronal ceroid lipofuscinosis. *Biochim Biophys Acta* 1862: 1324–1336. [PubMed: 27101989]
- Junaid MA, Pullarkat RK (1999) Increased brain lysosomal pepstatin-insensitive proteinase activity in patients with neurodegenerative diseases. *Neurosci Lett* 264: 157–160. [PubMed: 10320038]
- Katz ML, Johnson GS, Tullis GE, Lei B (2008) Phenotypic characterization of a mouse model of juvenile neuronal ceroid lipofuscinosis. *Neurobiol Dis* 29: 242–253. [PubMed: 17962032]
- Katz ML, Shibuya H, Liu PC, Kaur S, Gao CL, Johnson GS (1999) A mouse gene knockout model for juvenile ceroid-lipofuscinosis (Batten disease). *J Neurosci Res* 57: 551–556. [PubMed: 10440905]

- Katz ML, Tecedor L, Chen Y, et al. (2015) AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease. *Sci Transl Med* 7: 313ra180.
- Kovacs AD, Pearce DA (2015) Finding the most appropriate mouse model of juvenile CLN3 (Batten) disease for therapeutic studies: the importance of genetic background and gender. *Dis Model Mech* 8: 351–361. [PubMed: 26035843]
- Langin L, Johnson TB, Kovacs AD, Pearce DA, Weimer JM (2020) A tailored Cln3(Q352X) mouse model for testing therapeutic interventions in CLN3 Batten disease. *Sci Rep* 10: 10591. [PubMed: 32601357]
- Laqtom NN, Dong W, Medoh UN, et al. (2022) CLN3 is required for the clearance of glycerophosphodiester from lysosomes. *Nature* 609: 1005–1011. [PubMed: 36131016]
- Mekada K, Abe K, Murakami A, et al. (2009) Genetic differences among C57BL/6 substrains. *Exp Anim* 58: 141–149. [PubMed: 19448337]
- Meng Y, Sohar I, Sleat DE, et al. (2014) Effective intravenous therapy for neurodegenerative disease with a therapeutic enzyme and a peptide that mediates delivery to the brain. *Mol Ther* 22: 547–553. [PubMed: 24394185]
- Meng Y, Sohar I, Wang L, Sleat DE, Lobel P (2012) Systemic administration of tripeptidyl peptidase I in a mouse model of late infantile neuronal ceroid lipofuscinosis: effect of glycan modification. *PLoS One* 7: e40509. [PubMed: 22792360]
- Meng Y, Wiseman JA, Nemtsova Y, et al. (2017) A Basic ApoE-Based Peptide Mediator to Deliver Proteins across the Blood-Brain Barrier: Long-Term Efficacy, Toxicity, and Mechanism. *Mol Ther* 25: 1531–1543. [PubMed: 28456380]
- Mitchison HM, Bernard DJ, Greene ND, et al. (1999) Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected]. *Neurobiol Dis* 6: 321–334. [PubMed: 10527801]
- Mole SE, Williams RE, Goebel HH (2011) *The neuronal ceroid lipofuscinoses (Batten disease)*, Oxford: Oxford University Press.
- Nelvagal HR, Dearborn JT, Ostergaard JR, Sands MS, Cooper JD (2021) Spinal manifestations of CLN1 disease start during the early postnatal period. *Neuropathol Appl Neurobiol* 47: 251–267. [PubMed: 32841420]
- Palmer DN, Fearnley IM, Medd SM, et al. (1989) Lysosomal storage of the DCCD reactive proteolipid subunit of mitochondrial ATP synthase in human and ovine ceroid lipofuscinoses. *Adv Exp Med Biol* 266: 211–222; discussion 223. [PubMed: 2535017]
- Passini MA, Dodge JC, Bu J, et al. (2006) Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. *J Neurosci* 26: 1334–1342. [PubMed: 16452657]
- Rawlings ND, Barrett AJ (1999) Tripeptidyl-peptidase I is apparently the CLN2 protein absent in classical late-infantile neuronal ceroid lipofuscinosis. *Biochim Biophys Acta* 1429: 496–500. [PubMed: 9989235]
- Ru Y, Corado C, Soon RK, Jr., et al. (2019) Neurofilament light is a treatment-responsive biomarker in CLN2 disease. *Ann Clin Transl Neurol* 6: 2437–2447. [PubMed: 31814335]
- Schulz A, Ajayi T, Specchio N, et al. (2018) Study of Intraventricular Cerliponase Alfa for CLN2 Disease. *N Engl J Med* 378: 1898–1907. [PubMed: 29688815]
- Sleat DE, Donnelly RJ, Lackland H, et al. (1997) Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. *Science* 277: 1802–1805. [PubMed: 9295267]
- Sleat DE, Gin RM, Sohar I, et al. (1999) Mutational analysis of the defective protease in classic late-infantile neuronal ceroid lipofuscinosis, a neurodegenerative lysosomal storage disorder. *Am J Hum Genet* 64: 1511–1523. [PubMed: 10330339]
- Sleat DE, Tannous A, Sohar I, et al. (2017) Proteomic Analysis of Brain and Cerebrospinal Fluid from the Three Major Forms of Neuronal Ceroid Lipofuscinosis Reveals Potential Biomarkers. *J Proteome Res* 16: 3787–3804. [PubMed: 28792770]
- Sleat DE, Wiseman JA, El-Banna M, et al. (2004) A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-

- peptidase I activity and progressive neurodegeneration. *J Neurosci* 24: 9117–9126. [PubMed: 15483130]
- Sleat DE, Wiseman JA, El-Banna M, et al. (2019) Analysis of Brain and Cerebrospinal Fluid from Mouse Models of the Three Major Forms of Neuronal Ceroid Lipofuscinosis Reveals Changes in the Lysosomal Proteome. *Mol Cell Proteomics* 18: 2244–2261. [PubMed: 31501224]
- Sohar I, Lin L, Lobel P (2000) Enzyme-based diagnosis of classical late infantile neuronal ceroid lipofuscinosis: comparison of tripeptidyl peptidase I and pepstatin-insensitive protease assays. *Clin Chem* 46: 1005–1008. [PubMed: 10894849]
- Sondhi D, Hackett NR, Peterson DA, et al. (2007) Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector. *Mol Ther* 15: 481–491. [PubMed: 17180118]
- Sondhi D, Scott EC, Chen A, et al. (2014) Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene. *Hum Gene Ther* 25: 223–239. [PubMed: 24372003]
- Staropoli JF, Haliw L, Biswas S, et al. (2012) Large-scale phenotyping of an accurate genetic mouse model of JNCL identifies novel early pathology outside the central nervous system. *PLoS One* 7: e38310. [PubMed: 22701626]
- Vines DJ, Warburton MJ (1999) Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I. *FEBS Lett* 443: 131–135. [PubMed: 9989590]
- Weimer JM, Benedict JW, Getty AL, et al. (2009) Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis. *Brain Res* 1266: 93–107. [PubMed: 19230832]
- Wendt KD, Lei B, Schachtman TR, Tullis GE, Ibe ME, Katz ML (2005) Behavioral assessment in mouse models of neuronal ceroid lipofuscinosis using a light-cued T-maze. *Behav Brain Res* 161: 175–182. [PubMed: 15885820]
- Wiseman JA, Meng Y, Nemtsova Y, et al. (2017) Chronic Enzyme Replacement to the Brain of a Late Infantile Neuronal Ceroid Lipofuscinosis Mouse Has Differential Effects on Phenotypes of Disease. *Mol Ther Methods Clin Dev* 4: 204–212. [PubMed: 28345005]
- Worgall S, Sondhi D, Hackett NR, et al. (2008) Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. *Hum Gene Ther* 19: 463–474. [PubMed: 18473686]
- Xu S, Wang L, El-Banna M, Sohar I, Sleat DE, Lobel P (2011) Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis. *Mol Ther* 19: 1842–1848. [PubMed: 21730969]
- Yuan R, Meng Q, Nautiyal J, et al. (2012) Genetic coregulation of age of female sexual maturation and lifespan through circulating IGF1 among inbred mouse strains. *Proc Natl Acad Sci U S A* 109: 8224–8229. [PubMed: 22566614]

Synopsis

While the phenotype of a mouse model lacking both TPP1 and CLN3 appears essentially identical to a mouse lacking only TPP1, heterozygosity for mutations in the gene encoding TPP1 exacerbates the phenotype of mice lacking CLN3, suggesting potential functional interactions between two proteins associated with similar neurodegenerative diseases in children.




Figure 1. Survival analysis of $Tpp1$ and $Cln3$ mice.

A. Survival analysis of mice in a $Tpp1^{-/-}$. Data are included for $Tpp1^{-/-};Cln3^{+/+}$ in a C57BL/6 $Nnt^{+/+}$ background, a C57BL/6J $Nnt^{-/-}$ background and a mixed C57BL6 and C57BL6/J background (C57BL/6x6J). **B.** Survival analysis of mice in a $Tpp1^{+/-}$ or $Tpp1^{+/+}$ background. The Yuan survival dataset (Yuan et al 2012) was obtained from Jackson Laboratories (<https://phenome.jax.org/projects/Yuan2>) and comprised male and female mice in a C57BL/6J substrain background. **C.** Comparison of survival of $Tpp1^{+/-};Cln3^{-/-}$ animals from the current study with historical data for wild-type and $Tpp1^{+/-};Cln3^{-/-}$ animals (Katz

et al 2008). Data were obtained from ~equal numbers of male and female animals. Median survival and number of animals analyzed per genotype are shown in Table 1.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2. Astrocytosis and microglial activation in 120-day old $Tpp1^{-/-}Cln3^{+/+}$ and $Tpp1^{-/-}Cln3^{-/-}$ animals.

Immunofluorescence staining for the astrocyte marker glial fibrillary associated protein (GFAP, green) and microglial marker CD68 (red) reveals profound astrocytosis and microglial activation respectively, in the primary somatosensory cortex (S1BF) and ventral posterior thalamic nuclei (VPM/VPL) of both $Tpp1^{-/-}Cln3^{+/+}$ and $Tpp1^{-/-}Cln3^{-/-}$ animals, compared to relatively low levels of GFAP and CD68 immunoreactivity in the grey matter of $Tpp1^{+/-}Cln3^{-/-}$ and $Tpp1^{+/-}Cln3^{+/-}$, which is comparable to previously published data from wild type mice. Scale bar = 100µm and 25µm in inserts.




FIGURE 4. Relative protein expression in *Tpp1* and *Cln3* mutant mice determined by SPS-MS3 quantitation of isobaric-labeled peptides.

Comparisons are: A, *Tpp1*^{-/-}*Cln3*^{+/+} versus *Tpp1*^{+/+}*Cln3*^{+/+}; B, *Tpp1*^{-/-}*Cln3*^{-/-} versus *Tpp1*^{+/+}*Cln3*^{+/+}; C, *Tpp1*^{+/+}*Cln3*^{-/-} versus *Tpp1*^{+/+}*Cln3*^{-/-}; D, *Tpp1*^{+/+}*Cln3*^{-/-} versus *Tpp1*^{+/+}*Cln3*^{+/+}; E, *Tpp1*^{-/-}*Cln3*^{-/-} versus *Tpp1*^{-/-}*Cln3*^{+/+}; and, F, *Tpp1*^{+/+}*Cln3*^{-/-} versus *Tpp1*^{+/+}*Cln3*^{+/+}. Q values were calculated based on peptide data for each protein using the False Discovery Rate two-stage step up method of Benjamini, Krieger and Yekutieli. Dashed lines indicate an FDR of 1% (y axis) and arbitrary fold-change of 2-fold (x axis). Axes are truncated at Q value 1E-10 and ratios of 1/16 to 16. Red and black symbols indicate

known lysosomal (based on (17)) and other proteins, respectively. Names of select proteins of interest are shown in red (lysosomal) or black (other).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 5. Correlation between significant proteomic changes in animals of different genotypes. **A**, $Tpp1^{-/-};Cln3^{+/-}$ compared to $Tpp1^{-/-};Cln3^{-/-}$; goodness of fit, $R=0.7901$. Note that NNT is censored (see Results). **B**, $Tpp1^{+/-};Cln3^{-/-}$ compared to $Tpp1^{+/-};Cln3^{-/-}$; goodness of fit, $R=0.5752$. Compared to wild-type, proteins shown are significantly altered in at least one model (FDR 1%), have a magnitude of change of 1.5 fold in at least one model, and have a consistent direction of change in both models. Names of select proteins of interest are shown in red (lysosomal) or black (other). Filled symbols indicate proteins that are

significantly altered in *both* genotypes being compared, open symbols indicate proteins that are significantly altered *in one of the two* genotypes being compared.




Figure 6. TPP1 activity in mutant mice.

Activities were measured in brain extracts from 120-day old mice and genotypes were compared to wild-type using one-way ANOVA with Dunnett's test for multiple comparisons when compared to combined controls $Tpp1^{+/+}; Cln3^{+/+}$. *, $p < 0.05$; ***, $P < 0.001$; ****, $P < 0.0001$. Bars indicate mean and standard deviation.




Figure 7. TPP1 activity in the presence or absence of glycerophosphodiesteres.

Activity of indicated amounts of TPP1 was measured by endpoint assay using 200µM Ala-Ala-Phe-AMC substrate, with or without 1 or 10 mM L-α-glycerophosphorylcholine or 100µM glycerophosphoinositol.

Table 1.Survival statistics for *Tpp1*^{-/-} animals.

Genotype	Total n/ number of events	median survival	Log-rank (Mantel-Cox) test		significant
			P value	Compared to:	
<i>Tpp1</i> ^{-/-} ; <i>Cln3</i> ^{-/-} (C57BL/6x6J)	204/134	120	0.0114 0.0017	<i>Tpp1</i> ^{-/-} ; <i>Cln3</i> ^{+/+} (C57BL6x6J) <i>Tpp1</i> ^{-/-} ; <i>Cln3</i> ^{-/-} (C57BL6x6J)	no yes
<i>Tpp1</i> ^{-/-} ; <i>Cln3</i> ^{+/-} (C57BL/6x6J)	126/108	124	0.5239	<i>Tpp1</i> ^{-/-} ; <i>Cln3</i> ^{+/+} (C57BL6x6J)	no
<i>Tpp1</i> ^{-/-} ; <i>Cln3</i> ^{+/+} (C57BL/6x6J)	52/45	124	0.0007	<i>Tpp1</i> ^{-/-} ; <i>Cln3</i> ^{+/+} (C57BL6)	yes
* <i>Tpp1</i> ^{-/-} ; <i>Cln3</i> ^{+/+} (C57BL/6)	149/105	137	<0.0001	<i>Tpp1</i> ^{-/-} ; <i>Cln3</i> ^{+/+} (C57BL6J)	
* <i>Tpp1</i> ^{-/-} ; <i>Cln3</i> ^{+/+} (C57BL/6J)	22/47	112			
* <i>Tpp1</i> ^{+/+} ; <i>Cln3</i> ^{+/+} (C56BL/6)	1144/44	nd	0.4072	<i>Tpp1</i> ^{+/+} ; <i>Cln3</i> ^{+/+} (Yuan dataset, C57BL/6J)	no
<i>Tpp1</i> ^{+/+} ; <i>Cln3</i> ^{+/+} (Yuan dataset)	61/61	901			
<i>Tpp1</i> ^{+/+} ; <i>Cln3</i> ^{-/-} (C57BL/6x6J)	68/15	584	<0.0001	<i>Tpp1</i> ^{+/+} ; <i>Cln3</i> ^{-/-} (C57BL/6J and C57BL/6x6J)	yes
<i>Tpp1</i> ^{+/+} ; <i>Cln3</i> ^{+/-} (C57BL/6x6J)	228/18	748	0.5719 0.0014	<i>Tpp1</i> ^{+/+} ; <i>Cln3</i> ^{-/-} <i>Tpp1</i> ^{+/+} ; <i>Cln3</i> ^{+/+} (Yuan dataset)	no yes
* <i>Tpp1</i> ^{+/+} ; <i>Cln3</i> ^{+/+} (C57BL6)	1442/49	undefined	0.1635	<i>Tpp1</i> ^{+/+} ; <i>Cln3</i> ^{+/+} (Yuan dataset)	no
* <i>Tpp1</i> ^{+/+} ; <i>Cln3</i> ^{-/-} (C57BL/6J and C57BL/6x6J)	289/27	719	<0.0001	<i>Tpp1</i> ^{+/+} ; <i>Cln3</i> ^{+/+} (Yuan dataset)	yes
<i>Tpp1</i> ^{+/+} ; <i>Cln3</i> ^{-/-} (Katz dataset, C57BL/6J)	27/27	742	0.2339	<i>Tpp1</i> ^{+/+} ; <i>Cln3</i> ^{-/-} (C57BL/6J and C57BL/6x6J)	no

Survival data were obtained from littermates from crosses between double *Tpp1* and *Cln3* mutant crosses unless indicated otherwise (* for single mutant crosses). Significance for the Log-rank tests conducted below was evaluated after correction of P values for multiple comparisons using the Bonferroni method.